Saad Harti, founder and CEO of Swiss-based biotech Legacy Healthcare discusses the company’s positive Phase 2/3 data and filing of their lead prescription botanical drug Coacillium for the treatment of an autoimmune condition, alopecia areata. He also talks about a recent survey which found that patients would prefer prescription botanical drugs to treat their chronic diseases.
Saad Harti is founder & CEO of Legacy Healthcare, a company aiming to develop botanical drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile populations, e.g. children, cancer patients and the elderly. Saad has started in the financial field, at Arthur Andersen. He later co-founded Altacare, a healthcare business development firm active in more than 50 markets. Saad has pioneered contraceptive-access programs in developing countries.